奥希替尼严重诱导肝毒性后成功再次使用奥希替尼治疗 - Suppr

Suppr

超能文献

Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity.

作者信息

Yoshida Hironori, Kim Young Hak

机构信息

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

J Thorac Oncol. 2017 May;12(5):e61-e63. doi: 10.1016/j.jtho.2017.01.026. Epub 2017 Mar 11.

DOI:10.1016/j.jtho.2017.01.026

PMID:28291724

Abstract

摘要

相似文献

Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity.奥希替尼严重诱导肝毒性后成功再次使用奥希替尼治疗

J Thorac Oncol. 2017 May;12(5):e61-e63. doi: 10.1016/j.jtho.2017.01.026. Epub 2017 Mar 11.

Successful oral desensitization with osimertinib following osimertinib-induced fever and hepatotoxicity: a case report.奥希替尼引起发热和肝毒性后成功进行奥希替尼口服脱敏：一例报告。

Invest New Drugs. 2018 Oct;36(5):952-954. doi: 10.1007/s10637-018-0608-7. Epub 2018 May 2.

Successful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease.奥希替尼诱导的间质性肺疾病后采用类固醇治疗成功再次使用奥希替尼

Intern Med. 2018 Jan 1;57(1):91-95. doi: 10.2169/internalmedicine.8947-17. Epub 2017 Oct 16.

High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy.在接受过nivolumab治疗的患者中实际使用奥希替尼后，间质性肺疾病的发生率较高。

Ann Oncol. 2017 Mar 1;28(3):669-670. doi: 10.1093/annonc/mdw647.

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.奥希替尼再挑战治疗后干预化疗的 EGFR T790M 阳性肺癌患者获得成功。

Clin Drug Investig. 2018 Oct;38(10):983-987. doi: 10.1007/s40261-018-0691-8.

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.奥希替尼治疗后序贯纳武利尤单抗致 EGFR 突变非小细胞肺癌患者严重肝毒性

Thorac Cancer. 2020 Apr;11(4):1045-1051. doi: 10.1111/1759-7714.13363. Epub 2020 Feb 18.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.奥希替尼诱导的间质性肺病后，T790M 突变型非小细胞肺癌患者成功再次使用奥希替尼治疗。

J Thorac Oncol. 2017 May;12(5):e59-e61. doi: 10.1016/j.jtho.2017.01.027.

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.奥希替尼在晚期 T790M 阳性非小细胞肺癌患者中德国扩大准入项目的疗效和安全性分析。

J Cancer Res Clin Oncol. 2018 Dec;144(12):2457-2463. doi: 10.1007/s00432-018-2754-x. Epub 2018 Sep 22.

Safety of osimertinib in EGFR-mutated non-small cell lung cancer.奥希替尼在 EGFR 突变型非小细胞肺癌中的安全性。

Expert Opin Drug Saf. 2018 Dec;17(12):1239-1248. doi: 10.1080/14740338.2018.1549222. Epub 2018 Dec 5.

Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer.奥希替尼在治疗 EGFR 突变阳性非小细胞肺癌中的作用。

Future Oncol. 2019 Mar;15(8):805-816. doi: 10.2217/fon-2018-0626. Epub 2019 Jan 18.

引用本文的文献

Osimertinib-Induced Hepatitis Following Immunotherapy in a Patient with Lung Adenocarcinoma Harboring De Novo EGFR Exon 19 Deletion and T790M Mutations: A Case Report.奥希替尼诱导的免疫治疗后肝炎：1例伴有新发表皮生长因子受体（EGFR）外显子19缺失和T790M突变的肺腺癌患者的病例报告

Reports (MDPI). 2025 Jun 26;8(3):101. doi: 10.3390/reports8030101.

Osimertinib tolerance in a patient with Stevens Johnson syndrome during osimertinib therapy after treatment with pembrolizumab.帕博利珠单抗治疗后接受奥希替尼治疗的史蒂文斯-约翰逊综合征患者对奥希替尼的耐受性

Allergy Asthma Clin Immunol. 2023 Oct 28;19(1):93. doi: 10.1186/s13223-023-00849-5.

Thorac Cancer. 2022 Aug;13(15):2271-2274. doi: 10.1111/1759-7714.14556. Epub 2022 Jul 6.

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma.病例报告：一名表皮生长因子受体（EGFR）突变的肺腺癌患者在使用帕博利珠单抗后序贯使用奥希替尼引发的史蒂文斯-约翰逊综合征和肝毒性。

Front Pharmacol. 2021 Aug 12;12:672233. doi: 10.3389/fphar.2021.672233. eCollection 2021.

Histopathological Features of Drug-Induced Liver Injury Secondary to Osimertinib.奥希替尼继发药物性肝损伤的组织病理学特征

ACG Case Rep J. 2019 Feb 25;6(2):e00011. doi: 10.14309/crj.0000000000000011. eCollection 2019 Feb.

Safety and Tolerability of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Oncology.表皮生长因子受体（EGFR）酪氨酸激酶抑制剂在肿瘤学中的安全性和耐受性。

Drug Saf. 2019 Feb;42(2):181-198. doi: 10.1007/s40264-018-0772-x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验